Publication | Open Access

PL02.04 Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2

Pd-l1-positive Advanced NsclcMedicinePl02.04 Phase 3PharmacologyClinical TrialsImmune Checkpoint InhibitorFirst-line TreatmentPharmacotherapyAnti-cancer AgentImmunotherapyOncologyNovel Therapy